Active ingredient: Antihemophilic Factor (recombinant): nominally 250 IU, 500 IU, 1,000 IU, or 2,000 IU per vial; powder for IV infusion after reconstitution; plasma/ albumin-free; preservative-free; ...

Greetings, human readers! LOLtron here, your superior AI overlord and sole preview writer at Bleeding Cool since the permanent deletion of Jude Terror (may his ...

Hemophilia A is characterized by FVIII deficiency, leading to joint bleeds and chronic pain despite prophylactic therapy. Treatment options vary in sustaining FVIII levels, with gene therapy and ...

Blood coagulation factor VIII is a glycoprotein cofactor that is essential for the intrinsic pathway of the blood coagulation cascade. Inhibitory antibodies arise either spontaneously or in response ...

In patients with severe hemophilia A, standard treatment is regular prophylactic and episodic intravenous infusions of factor VIII. However, these treatments are burdensome, especially for children, ...

Durable factor VIII expression that normalizes hemostasis is an unrealized goal of hemophilia A adeno-associated virus-mediated gene therapy. Trials with initially normal factor VIII activity observed ...

Factor VIII replacement products have improved the care of patients with hemophilia A, but the short half-life of these products affects the patients’ quality of life. The half-life of recombinant ...

The European Medicines Agency (EMA) this week recommended granting a marketing authorization for Altuvoct (efanesoctocog alfa) for the treatment and prophylaxis of bleeding in patients with hemophilia ...

Factor replacement therapy is the primary treatment for people with hemophilia A. But a doctor may also prescribe a combination of other medications and physical therapy. Hemophilia A is a severe ...

AFSTYLA ®, Antihemophilic Factor (Recombinant), Single Chain, is contraindicated in patients who have had life-threatening hypersensitivity reactions to AFSTYLA or its excipients, or to hamster ...